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Sir,
It is reported that 7 years after the start of screening in Sweden,
the incidence of invasive breast cancer in the screened age group
was 69% higher than expected (Duffy et al, 2008). After adjustment
for a lead time of 2.4 years and for the increased use of hormone
replacement therapy, they found 39% excess.
We have reservations about adjustments for lead time (Zahl
et al, 2008). Correction for lead time should only be done for those
cancers that would have been diagnosed at a later time in the
absence of screening. But many screen-detected cancers would not
have come to the women’s attention in their remaining lifetime, if
they had not attended screening and are by definition over-
diagnosed. If these cancers are not excluded from the calculation
of lead time, the lead-time distribution will be artificially right-
skewed, and the average lead time will appear to be much longer
than it really is. Duffy et al, (2008) did not exclude such cancers
from the calculation of lead time, but counted all excess cancers
detected in a randomised trial as advanced diagnoses, when some
of them were in fact overdiagnosed cases. They have therefore
overestimated the lead-time effect.
Duffy et al (2008) recognise that the detection of non-overdiagnosed
cancers should give rise to a drop in incidence when the women leave
the screening programme. Quantifying such a compensatory drop is a
less bias-prone method for adjusting the incidence increase for lead-
time effects, as it makes no assumption about the average lead time. It
is also very simple to use (see, e.g., Zahl et al, 2004).
We have done a systematic review of incidence trends in
countries with organised mammography screening that presented
data on breast cancer incidence for both screened and non-
screened age groups for at least 7 years before screening and 7
years after screening had been fully implemented (Jørgensen and
Gøtzsche, 2008). We were able to include data from United
Kingdom, Canada, Australia, Sweden and Norway. We found that
compensatory drops in the older age groups were small or absent,
although major drops would have been expected if the lead time of
2.4 years were true. When we adjusted for these drops, we found
36% overdiagnosis of invasive breast cancer, in good agreement
with the results of Duffy et al (2008), and 51% when we included
carcinoma in situ.
Duffy et al (2008) mention that after prolonged follow-up
of the Malmo ¨ randomised screening trial, an overdiagnosis of
7–8% was reported and they find this estimate considerably
more plausible than their own estimate of 39%. However,
they have overlooked that the former estimate is seriously flawed
(Zahl et al, 2008). There was substantial opportunistic screening
in the control group and after adjustment for this, the
overdiagnosis estimate in the Malmo ¨ trial is 24% (Gøtzsche and
Jørgensen, 2006).
It is asserted that after adjustments, overdiagnosis estimates will
be smaller than many rates quoted in the past (Duffy et al, 2008).
We disagree, as most ‘rates quoted in the past’ have been too small
(Gøtzsche and Nielsen, 2006). On the basis of randomised trials, the
overdiagnosis is 30% (Gøtzsche and Nielsen, 2006), and it becomes
44% if adjusted for opportunistic screening in the control groups
(Jørgensen and Gøtzsche, 2008). The low rates in the past have been
too low for the very reason that they have been based on flawed
lead-time models (Jørgensen and Gøtzsche, 2008; Zahl et al, 2008).
We believe the most reliable estimate for organised mammography
screening is 51% (Jørgensen and Gøtzsche, 2008). This means that
one in three breast cancers detected in a population offered
organised mammography screening are overdiagnosed. Many
women are therefore harmed substantially by screening, as
practically all detected carcinoma in situ cases and invasive cancers
are treated, at great physical and psychological costs.
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